Skip to content
OpenCapital
Get started

Anika Therapeutics ANIK Divestiture of businesses, net of cash transferred

Divestiture of businesses, net of cash transferred at other companies

Enovis logo
EnovisENOV
——

Other financials

Income statement

See full
Revenue$29.6M+13.2%
Net income-$5.1M-3.8%

Balance sheet

See full
Cash & equivalents$41.0M-23.1%
Total debt$25.7M+1.2%
Total equity$133.9M-9.8%
Total assets$179.4M-5.9%

Cash flow

See full
Operating cash flow-$4.8M-3,628%
CapEx$1.4M-49.3%
Free cash flow-$6.3M-112%

Valuation

See full
Market cap$204.37M+31.6%
Enterprise value$189.09M+48.7%
P/S1.8×+0.1×

Profitability

See full
Net margin-9.8%-4.4pp
FCF margin0.9%—

Returns & leverage

See full
Return on equity-8%-3.4pp
Debt / equity0.2×0.0×
Current ratio4.5×-1.3×

Where this comes from

Reported directly by Anika Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromDivestitureOfBusinessesNetOfCashDivested.

The official record: Anika Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Anika Therapeutics's divestiture of businesses, net of cash transferred.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Anika Therapeutics's divestiture of businesses, net of cash transferred?
Anika Therapeutics (ANIK) reported divestiture of businesses, net of cash transferred of $0 in Q1 2026.
How has Anika Therapeutics's divestiture of businesses, net of cash transferred changed year-over-year?
Anika Therapeutics's divestiture of businesses, net of cash transferred decreased by 100.0% year-over-year, from $4.5M to $0.